SEC Tracker
Get the app
IBIO · XBRL financial data

iBio financial statements, every quarter

The same tables from 14 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (IBIO's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue500*0*—————————
Revenue from contracts with customers500*0*year only02000200*10000*0*
Research and development1,6061,5359041,140*1,3051,8771,9063,224*3,5504,2803,2548,559*
General and administrative3,5472,9612,7222,444*2,8012,7422,9732,174*2,5015,1655,111(2,182)*
Total operating expenses5,1534,4963,6263,584*4,1064,6194,8795,398*6,0519,4458,36511,380*
Operating income (loss)(5,103)(4,496)(3,626)(3,409)*(4,106)(4,419)(4,879)(5,198)*(5,951)(9,445)(8,365)(11,380)*
Interest income554243223*1741127279*267493657733*
Interest expense26345260*57575444*364122(46)*
Income tax expense (benefit)0000*0000*0000*
Net income (loss)(5,746)(8,211)(3,172)(7,778)*(3,989)(4,364)(4,861)(5,163)*(5,720)(8,993)(7,730)(10,601)*
Earnings per share, basic‡ USD per share(4.80)(4.42)(0.85)—(0.46)(0.48)(0.49)—(0.11)(0.09)(0.06)—
Earnings per share, diluted‡ USD per share(4.80)(4.42)(0.85)—(0.46)(0.48)(0.49)—(0.11)(0.09)(0.06)—
Weighted average shares, basic‡ thousands of shares1,1981,8563,713—8,6339,1329,862—52,98199,133119,600—
Weighted average shares, diluted‡ thousands of shares1,1981,8563,713—8,6339,1329,862—52,98199,133119,600—
  • ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (November 2023); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal quarters (IBIO's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents1,4612,7885,30214,21011,0387,0154,9598,58228,11128,67247,63156,395
Marketable securities———0———021,45624,02627,16631,600
Accounts receivable0——0————65———
Inventory0000————————
Prepaid and other current assets4518948627496671,2571,1011,0341,1406702,4543,078
Total current assets23,02219,69936,13915,67211,7058,2856,0609,72150,77253,36877,25192,221
Property and equipment, net4,0543,8903,7263,6323,5113,3913,2843,1633,2103,4473,3103,086
Right-of-use asset2,6452,5652,4722,4012,3172,2302,1422,0511,9581,8641,7661,667
Total assets37,67834,02250,15428,73424,51721,69719,10323,18564,15564,39385,83499,110
Accounts payable1,9111,8591,2283588556141,4772,1882,8222,6543,0354,423
Accrued liabilities3,3913,7573,9982,0281,0771,8351,3251,3458501,5791,7875,626
Total current liabilities20,70821,55321,4263,8403,4694,7095,3976,1066,0485,9016,50411,745
Lease liability, non-current3,0212,9122,8012,6882,5722,4502,3252,1992,0681,9321,7931,652
Total liabilities24,46924,82525,2917,4106,7637,8027,7228,3058,1167,8338,29713,397
Accumulated deficit(294,686)(302,897)(306,069)(313,847)(317,836)(322,200)(327,061)(332,224)(337,944)(346,937)(354,667)(365,268)
Total stockholders' equity13,2099,19724,86321,32417,75413,89511,38114,88056,03956,56077,53785,713
Total liabilities and equity37,67834,02250,15428,73424,51721,69719,10323,18564,15564,39385,83499,110
Common shares outstanding (cover page)‡ thousands of shares1,4053,4848,6248,6389,1499,87516,51919,65522,48734,54449,67964,307
  • ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (November 2023); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal quarters (IBIO's year ends in late June)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(5,746)(8,211)(3,172)(7,778)*(3,989)(4,364)(4,861)(5,163)*(5,720)(8,993)(7,730)(10,601)*
Stock-based compensation765456*457*360*415475*370*270*323253*377*420*
Net cash from operating activities(5,340)(4,706)*(3,654)*(4,854)*(3,715)(3,869)*(3,105)*(4,615)*(5,665)(5,241)*(6,084)*(6,228)*
Purchases of property and equipment——0*210*01*14*1*32516*11*19*
Net cash from investing activities500*1,000*(144)*713(2)*(14)*45*(21,493)(2,983)*(3,111)*(4,412)*
Proceeds from issuing common stock2,8084,119*4,277*14,319*40*1,127*2,410*2190*3,310*0*
Net cash from financing activities2,4724,005*5,025*12,992*(162)(152)*1,063*8,180*46,7058,785*28,154*19,404*
Net change in cash(2,818)(701)*2,371*7,994*(3,164)(4,023)*(2,056)*3,610*19,547561*18,959*8,764*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
iBio56,3950*(6,228)*64.3M14.1 quarters 10-KJun 30, 2026
Sutro Biopharma54,3359,839(38,290)*16.6M4.3 quarters 10-QJun 30, 2026
PDS Biotechnology5,596not reported(2,793)*56.0M2.0 quarters 10-QJun 30, 2026
Avalo Therapeutics85,382not reported(19,988)*53.6M20.0 quarters 10-QJun 30, 2026
Medicinova25,416458(1,920)*49.2M13.2 quarters 10-QJun 30, 2026
Cue Biopharma17,3927,877(29,004)*7.3M0.6 quarters 10-QJun 30, 2026
Lifevantage14,92042,377*4,767*12.5M— 10-KJun 30, 2026
Veru23,880not reported(5,467)*17.1M4.4 quarters 10-QJun 30, 2026
Whitehawk Therapeutics85,2340(14,529)*57.0M13.1 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.